Regeneron Pharmaceuticals Inc. REGN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · regeneron.com
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for eye diseases, allergic and inflammatory conditions, cardiovascular and metabolic diseases, cancer, infectious diseases, and rare disorders. Key products include EYLEA for macular degeneration, Dupixent for atopic dermatitis and asthma, and Libtayo for certain skin cancers. The company is headquartered in Tarrytown, New York.
Key ratios
FreeCashFlowOnSale TTM 0.28
FreeCashFlowOnSale 2025 0.28
FreeCashFlowOnSale 2024 0.26
FreeCashFlowOnSale 2023 0.3
NetIncomeMargin TTM 0.31
NetIncomeMargin 2025 0.31
NetIncomeMargin 2024 0.31
NetIncomeMargin 2023 0.3
ReturnOnAssets TTM 0.06
ReturnOnAssets 2025 0.06
ReturnOnAssets 2024 0.07
ReturnOnAssets 2023 0.08
ReturnOnEquity TTM 0.15
ReturnOnEquity 2025 0.15
ReturnOnEquity 2024 0.16
ReturnOnEquity 2023 0.16
Recent news
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
2026-07-31 · GlobeNewswire
Regeneron Reports Second Quarter 2026 Financial and Operating Results
2026-07-30 · GlobeNewswire
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
2026-06-25 · GlobeNewswire